PPARG and metabolic dysfunction-associated steatotic liver disease: The PPARγ agonists rosiglitazone and pioglitazone were shown to improve NAFLD-related features of hepatic steatosis, ballooning, inflammation, and in several studies, also stage of fibrosis in non-diabetic, prediabetic and T2DM patients with NAFLD [20,21,22,23].